Procarbazine, lomustine and vincristine for recurrent highgrade glioma

Medicine and Dentistry

• Adverse Event 17%
• Arm 17%
• Clinical Oncology 5%
• Clinical Trial 5%
• Controlled Clinical Trial 5%
• Critical Appraisal 5%
• Ganglioglioma 100%
• Hazard Ratio 11%
• Lomustine 100%
• Meta-Analysis 5%
• Neuro-Oncology 17%
• Overall Survival 17%
• Procarbazine 100%
• Progression Free Survival 23%
• Quality of Life 29%
• Randomized Controlled Trial 29%
• Recurrent Disease 17%
• Second-Line Chemotherapy 5%
• Supportive Care 5%
• Temozolomide 52%
• Treatment Option 5%
• Vincristine 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 17%
• Chemotherapy 58%
• Clinical Trial 5%
• Controlled Clinical Trial 5%
• Lomustine 100%
• Nitrosourea 5%
• Overall Survival 17%
• Procarbazine 100%
• Progression Free Survival 23%
• Randomized Controlled Trial 29%
• Recurrent Disease 17%
• Second-Line Chemotherapy 5%
• Temozolomide 52%
• Vincristine 100%

Nursing and Health Professions

• Adverse Event 17%
• Cochrane Library 5%
• Critical Appraisal 5%
• Embase 5%
• Hazard Ratio 11%
• Health Care Quality 5%
• Lomustine 100%
• Meta Analysis 5%
• National Health Organization 5%
• Nitrosourea 5%
• Overall Survival 17%
• Practice Guideline 11%
• Procarbazine 100%
• Progression Free Survival 23%
• Quality of Life 29%
• Recurrent Disease 17%
• Sample Size 5%
• Temozolomide 52%
• Vincristine 100%
• World Health Organization 5%